To include your compound in the COVID-19 Resource Center, submit it here.

Prima targets NASDAQ

Australian cancer immunotherapy play Prima BioMed seeks NASDAQ listing

Prima targets NASDAQ

Australia's Prima BioMed Ltd. (ASX:PRR) hopes to capitalize on the substantial interest in fellow cancer immunotherapy play Dendreon Corp. (NASDAQ:DNDN) by listing on NASDAQ.

CEO Martin Rogers said the company is awaiting clearance for the listing from the SEC. "A lot of

Read the full 434 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE